We are CSL Seqirus. One of the world's largest influenza vaccine manufacturers and the only company fully dedicated to influenza prevention. Behind our nearly century-long mission of prevention are thousands of passionate professionals with deep, technical expertise in influenza. flu360® channels that expertise into an experience that helps give you the upper hand in the fight against flu.
Ready to realize the benefits of flu360?
Influenza innovations
Adjuvanted option
Cell-based option
CSL Seqirus is committed to transforming how flu vaccines are designed, developed, and manufactured. Adjuvanted influenza vaccines and cell-based manufacturing are 2 of our technologies.
An adjuvant is a substance added to a vaccine to boost the immune response.1 An adjuvant may be used to help address seasonal influenza among older adults, which disproportionately impacts this population.2 CSL Seqirus is putting such innovation to work in an adjuvanted seasonal influenza vaccine.
Not all flu vaccines are made the same way.3 Cell-based manufacturing is a different production process compared to traditional, egg-based manufacturing.4 As the largest cell-based influenza vaccine manufacturer in the world, CSL Seqirus is on the very edge of this technology and ready to help you navigate it.
Influenza innovations
CSL Seqirus is committed to transforming how flu vaccines are designed, developed, and manufactured. Adjuvanted influenza vaccines and cell-based manufacturing are 2 of our technologies.
Explore the innovation of our vaccine portfolio
Adjuvanted option
An adjuvant is a substance added to a vaccine to boost the immune response.1 An adjuvant may be used to help address seasonal influenza among older adults, which disproportionately impacts this population.2 CSL Seqirus is putting such innovation to work in an adjuvanted seasonal influenza vaccine.
Discover our adjuvanted influenza vaccineCell-based option
Not all flu vaccines are made the same way.3 Cell-based manufacturing is a different production process compared to traditional, egg-based manufacturing.4 As the largest cell-based influenza vaccine manufacturer in the world, CSL Seqirus is on the very edge of this technology and ready to help you navigate it.
Discover our cell-based influenza vaccineOur innovation is international, including research and production capabilities and best-in-class manufacturing facilities across 3 continents.*
A state-of-the-art facility specializing in an advanced cell-based process that utilizes cell-derived seed strains-a manufacturing alternative to traditionally manufactured influenza vaccines.
Learn more about our global capabilities and expertise at seqirus.us
One of Europe's largest biotechnology sites, the UK's only injectable influenza vaccine facility, and the facility that produces the world's only licensed adjuvanted seasonal influenza vaccine.
Learn more about our global capabilities and expertise at seqirus.us
Our Australian headquarters has been steadily producing influenza vaccines for the past 50 years, focusing solely on egg-based manufacturing.
Learn more about our global capabilities and expertise at seqirus.us
A state-of-the-art facility specializing in an advanced cell-based process that utilizes cell-derived seed strains-a manufacturing alternative to traditionally manufactured influenza vaccines.
One of Europe's largest biotechnology sites, the UK's only injectable influenza vaccine facility, and the facility that produces the world's only licensed adjuvanted seasonal influenza vaccine.
Our Australian headquarters has been steadily producing influenza vaccines for the past 50 years, focusing solely on egg-based manufacturing.
*Products distributed by CSL Seqirus USA Inc. can only be shipped within the US.
References: 1. Garçon N, Leroux-Roels G, Cheng WF. Vaccine adjuvants. Understanding Modern Vaccines: Perspectives in Vaccinology. 2011;1(1):89-113. 2. CDC. Flu & people 65 years and older. Accessed February 2, 2021. https://www.cdc.gov/flu/highrisk/65over.htm 3. CDC. How influenza (flu) vaccines are made. Accessed February 2, 2021. https://www.cdc.gov/flu/prevent/how-fluvaccine-made.htm 4. Rajaram S, Boikos C, Gelone DK, Gandhi A. Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Ther Adv Vaccines Immunother. 2020;8:2515135520908121. doi:10.1177/2515135520908121
